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http://dx.doi.org/10.1016/j.ccr.2013.03.013SUMMARYNearly 90% of human melanomas contain inactivated wild-type p53, the underlying mechanisms for which
are not fully understood. Here, we identify that cyclin B1/CDK1-phosphorylates iASPP, which leads to the in-
hibition of iASPP dimerization, promotion of iASPP monomer nuclear entry, and exposure of its p53 binding
sites, leading to increased p53 inhibition. Nuclear iASPP is enriched in melanomametastasis and associates
with poor patient survival. Most wild-type p53-expressingmelanoma cell lines coexpress high levels of phos-
phorylated nuclear iASPP, MDM2, and cyclin B1. Inhibition of MDM2 and iASPP phosphorylation with small
molecules induced p53-dependent apoptosis and growth suppression. Concurrent p53 reactivation and
BRAFV600E inhibition achieved additive suppression in vivo, presenting an alternative formelanoma therapy.INTRODUCTION
Advanced melanoma often harbors activating mutations in the
RAS-BRAF-MAPK, p16ink4a-Rb, and p14ARF-p53 tumor sup-
pressor pathways. The importance of RAS and RAF oncogenes
in melanoma development and maintenance is underscored by
the recent success of BRAF inhibitors, such as vemurafenib,
as therapeutic agents. Vemurafenib selectively inhibits the prolif-
eration of tumor cells harboring the BRAFV600Emutation, which
is present in 50% of human melanomas (Joseph et al., 2010).
Despite promising efficacy on initial treatment, most vemurafe-Significance
Metastatic melanoma is resistant to treatment and accounts
melanoma is an attractive therapeutic strategy, as nearly 90%
type p53. Nutlin3, an agonist of p53, is currently in clinical trials
We found that concurrent inhibition of MDM2 and iASPP with
growth suppression of melanoma cells in vitro and in vivo. Rea
apoptosis and suppressed melanoma growth, presenting an a
618 Cancer Cell 23, 618–633, May 13, 2013 ª2013 Elsevier Inc.nib-treated patients relapse within months due to acquired
drug resistance. Thus, cotargeting BRAFV600E and MEK has
been suggested (Poulikakos and Solit, 2011).
An alternative would be to cotarget two independent path-
ways that are both critical in melanoma development and main-
tenance. The p53 tumor suppressor pathway is of particular
interest. Over 80% of human melanomas express p53 that has
the wild-type (WT) sequence but often has impaired function,
some of which also have the BRAFV600E mutation. p53 inactiva-
tion can be achieved by a deletion in the p16ink4a locus, which
inactivates both p16ink4aand p14ARF, and occurs in 50% offor 80% of skin cancer deaths. Restoring p53 function in
of human melanomas express functionally defective wild-
, but often fails to reactivate p53 function when used alone.
small molecules resulted in p53-dependent apoptosis and
ctivation of p53 together with BRAFV600E inhibition induced
lternative strategy for melanoma therapy.
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Restoring p53 Function in Melanomamelanomas (Curtin et al., 2005). Mutation of p14ARF impairs its
ability to prevent MDM2, an E3 ubiquitin ligase of p53, from tar-
geting p53 for degradation (Zhang et al., 1998). The p53 stress
signal response is often defective in p14ARF mutant melanoma
cells (Yang et al., 2005), and p53 prevents progression of nevi
to melanoma in a transgenic mouse model (Terzian et al.,
2010). Overexpression of MDM2 or MDMX, which bind and inac-
tivate p53, is observed in melanomas (Gembarska et al., 2012;
Muthusamy et al., 2006; Polsky et al., 2001).
To restore p53’s tumor suppressive function in human tumors
expressing WT p53, p53 agonists such as Nutlin3 have been
developed (Vu and Vassilev, 2011). Nutlin3 suppresses tumor
growth by preventing MDM2 from binding to and targeting p53
for degradation. However, Nutlin3 alone only causes modest re-
activation of p53 in WT p53-expressing melanoma cells (de
Lange et al., 2012; Ji et al., 2012) and induces only p53-mediated
cell cycle arrest but not apoptosis (Tseng et al., 2010). Cell cycle
arrest is a reversible process, whereas apoptosis is irreversible.
Thus, the identification of ways to reactivate p53’s apoptotic
function is crucial. In over 60% of melanoma cell lines tested,
WT p53 lost its normal transcriptional activities (Houben et al.,
2011). p53-targeted apoptosis genes are often underexpressed
in WT p53-expressing melanomas (Avery-Kiejda et al., 2011),
thus WT p53 may lose its apoptotic function in these cells.
iASPP, which is encoded by PPP1R13L, is evolutionarily
conserved from Caenorhabditis elegans to humans (Bergama-
schi et al., 2003). The C termini of all three ankyrin repeat, SH3
domain, and proline-rich region containing protein (ASPP)
members (ASPP1, ASPP2, and iASPP) have similar motifs and
domain organization, but iASPP’s N terminus is distinct from
the others. Functionally, ASPP1 and ASPP2 stimulate, whereas
iASPP inhibits, p53-induced apoptosis; mainly by preferentially
regulating its transcriptional activity on apoptosis- (but not
cell cycle arrest) related genes (Bergamaschi et al., 2006b;
Samuels-Lev et al., 2001). Overexpression of iASPP is associ-
ated with chemoresistance in human cancer (Jiang et al.,
2011). iASPP inhibits both cellular senescence in vitro and
epithelial stratification of epidermis and esophagus in vivo. It is
mostly expressed as a nuclear protein in basal epithelial cells
that coexpress p63, typical of a proliferative epidermal compart-
ment. iASPP becomes cytoplasmic in differentiated epithelial
cells (Chikh et al., 2011; Notari et al., 2011). iASPP’s N terminus
is required for its cytoplasmic localization (Slee et al., 2004).
Because many iASPP-interacting proteins are transcription
factors (i.e., p53, p63, and NF-kB) (Bergamaschi et al., 2003;
Notari et al., 2011; Yang et al., 1999), it is likely that nuclear iASPP
is more active than cytoplasmic iASPP in regulating transcrip-
tion. Thus, iASPP’s ability to inhibit p53’s apoptotic function in
human melanoma was studied.
RESULTS
p53 Selectively Binds Slow-Migrating Nuclear iASPP
that Is Enriched in Metastatic Melanomas
iASPP expression and localization in 142 human melanomas
was examined. Cytoplasmic iASPP was mostly detected in
primary melanomas, whereas nuclear iASPP was mainly found
in metastases (Figure 1A). Most lymph node metastases ex-
pressed higher nuclear iASPP than primary tumors (>2-fold,p < 0.05), suggesting an association with advanced stage
cancers (Figure 1B). Full clinical follow-up information was avail-
able for 66/142 melanomas. High nuclear iASPP levels were
associated with poor patient survival (Figure 1C, p < 0.01).
iASPP was mainly cytoplasmic in human primary melanocytes
and in a panel of nonmelanoma tumor cell lines. However,
nuclear iASPP was enriched in most of melanoma cell lines
examined (Figure S1A available online; data not shown). Nuclear
iASPP was detected in the WT p53-expressing melanoma cell
line WM115 whereas both cytoplasmic and nuclear iASPP
were detected in the mutant p53-expressing melanoma cell
line SK-MEL37. Mainly, cytoplasmic iASPP was detected in
the p53 null human lung cancer cell line H1299 (Figure 1D).
Although iASPP migrated as two bands in all three cell lines,
it mostly migrated as a slower single band in WM115 but as
a faster single band in H1299 cells. We detected two iASPP
bands in SK-MEL37 cells, the mobilities of which corresponded
with those detected in WM115 and H1299 cells (Figure 1D).
Thus, nuclear localization of iASPP associates with slower
migration. A similar association was seen in all cell lines
examined (Figures S1B and S1C). p53 selectively coimmunopre-
cipitated slow-migrating iASPP in the panel of melanoma cell
lines tested (Figure 1E). This was most evident in WM278 cells
in which p53 mainly bound slow-migrating iASPP, even though
its expression was lower than that of fast-migrating iASPP (Fig-
ure 1E). These data suggest that slow-migrating nuclear iASPP
is a more active p53 inhibitor than fast-migrating cytoplasmic
iASPP. This is consistent with the in vivo finding that nuclear
iASPP is enriched in metastatic melanomas and associates
with poor survival.
Mitotic Arrest Induces Slow-Migrating Nuclear iASPP
Treatment of H1299, WM278, and B16 cells with various agents
showed that slow-migrating iASPP was specifically induced by
mitotic inducers such as nocodazole, paclitaxel, and colchicine.
Doxorubicin, staurosporine, cisplatin, and hydrogen peroxide,
which do not induce mitosis, had minimal effect (Figure 2A). As
mitotic cells often detach from tissue culture dishes, floating
cells were separated from adherent cells after nocodazole and
paclitaxel treatment. Figure 2B shows the enrichment of slow-
migrating iASPP in floating cell populations of cells treated with
mitotic inducers. Moreover, slow-migrating iASPP was mainly
found in naturally occurring G2/M phase cells enriched by
shake-off, confirmed by the presence of phosphohistone H3
(Figure 2C) and FACS analysis (Figure S2A). Nuclear iASPP
was detected in some H1299 and most WM278 floating cells
(Figure 2D). Adherent H1299 cells only expressed cytoplasmic
iASPP whereas adherent WM278 cells expressed both forms
(Figure 2C). Nocodazole clearly increased slow-migrating iASPP
in a panel of melanoma lines expressing both slow and fast-
migrating isoforms (Figure 2E), demonstrating that the observed
regulation of iASPP migration is a general phenomenon.
H1299 and WM278 cells were treated with stimuli such as
EDTA or cold shock to induce cell detachment but not mitosis.
Both treatments failed to affect iASPP mobility in H1299 cells
and had minimal effects on WM278, although nocodazole
induced large increases in slow migrating iASPP under the
same conditions (Figure S2B). These data show that mitotic sig-
nals induce slow-migrating iASPP, not cell detachment.Cancer Cell 23, 618–633, May 13, 2013 ª2013 Elsevier Inc. 619
Figure 1. p53 Selectively Binds Slow-
Migrating Nuclear iASPP that Is Enriched
in Metastatic Melanomas
(A and B) Example of iASPP staining pattern (A)
and the percentage of samples expressing high
nuclear iASPP (B) in 142 human primary and
metastaticmelanoma tissue array cores. Scale bar
represents 50 mm.
(C) Survival curves of patients with low or high
nuclear iASPP expression. n, number of samples
analyzed.
(D) Immunofluorescence staining showing iASPP
cellular localization (left panel, green) and immu-
noblot showing iASPP mobility (right panel) in
indicated cells. Topro (blue) marks nuclei. Scale
bar represents 20 mm.
(E) Immunoprecipitation to determine binding
between endogenous iASPP and p53 in human
melanoma cell lines as indicated. Cell lysates are
labeled as input.
In (D) and (E), arrows and arrowheads mark posi-
tions of fast or slow-migrating iASPP isoforms
respectively.
See also Figure S1.
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B1/CDK1 Contributes to iASPP Slow Migration
To identify the iASPP regions responsible for slowmigration, two
V5-tagged iASPP truncation mutants, iASPP(1–478)-V5 and
iASPP(482–828)-V5, were transfected into H1299 or SK-MEL37
cells, which mainly express unmodified iASPP. The transfected
cells were treated with nocodazole or paclitaxel to induce
mitosis. Mobility shifts were detected by anti-V5 antibody.
Slow-migrating iASPP(1–478)-V5 was specifically induced in
nocodazole or paclitaxel-treated cells (Figure 3A). Under the
same conditions, iASPP(482–828)-V5 mainly migrated as a
single band, indicating that modifications in the N-terminal half
of iASPP are primarily responsible for slow migration of iASPP
caused by mitotic inducers.
Recombinant N-terminal iASPP fragments iASPP(1–240) and
iASPP(249–482) were tested in an in vitro kinase assay using620 Cancer Cell 23, 618–633, May 13, 2013 ª2013 Elsevier Inc.purified cyclin B1/CDK1. iASPP(1–240),
but not iASPP(249–482), interacted with
CDK1 and was phosphorylated by cyclin
B1/CDK1 in vitro (Figures 3B and 3C).
S84, S113, and S120 were identified as
potential cyclin B1/CDK1 phosphoryla-
tion sites in iASPP(1–240). These sites
were singly or doubly mutated to alanine
to generate iASPP(1–240) mutants
(S84A; S113A; S120A; S84A/S113A;
S84A/S120A). The results in Figure 3D
show that cyclin B1/CDK1 failed to phos-
phorylate iASPP(1–240)S84A/S113A,
whereas all other phosphorylation mu-
tants could be phosphorylated in vitro.
The impact of iASPP S84/S113 phos-
phorylation by cyclin B1/CDK1 on iASPP
migration was tested by transfecting
iASPP and its nonphosphorylatable andphosphomimetic mutants, iASPP(S84A/S113A) and iASPP
(S84D/S113D), intomelanoma cell lines IGR37 and IGR39, which
mainly express slow- and fast-migrating iASPP, respectively. In
IGR37 and IGR39 cells, endogenous iASPPwasmainly detected
as slow and fast-migrating isoforms, respectively (Figure 3E,
LX49.3 panel). Within the same set of lysates, slow-migrating
iASPP-V5 was detected in IGR37 cells, whereas iASPP-V5 was
fast-migrating in IGR39 cells. iASPP(S84D/S113D) produced
partial slow-migrating iASPP in IGR37 cells, but not in IGR39
cells. In both IGR37 and IGR39 cells, iASPP(S84A/S113A) was
as a single fast-migrating iASPP band (Figure 3E, iASPP-V5
panel). Thus, transfected iASPP-V5 has a similar migration
pattern to endogenous iASPP. Phosphorylation of iASPP at
S84 and S113 contributed to its slow migration in SDS-PAGE.
Mass spectrometry analysis confirmed that endogenous iASPP
from H1299 cells was phosphorylated on S84 and S113 in
Figure 2. Mitotic Arrest Induces Slow-
Migrating Nuclear iASPP
(A) iASPP is detected by immunoblotting in H1299,
WM278, or B16 cells treated as indicated condi-
tions (Ctr: DMSO).
(B) Various cells were treated with the indicated
agents (Ctr, DMSO; Noco, nocodazole) for 16 hr.
Floating and adherent cells were separated by cell
shake-off. iASPP in cell lysates was immuno-
blotted.
(C) iASPP in floating and adherent H1299,WM278,
or human primary melanocytes separated by cell
shake-off was immunoblotted. Expression levels
of total and phosphorylated histone H3 were used
as a loading control and indicator of enrichment of
G2/M cells, respectively.
(D) Collected floating cells were seeded onto
slides by cytospin and stained with anti-iASPP
antibody by immunofluorescence. White arrow-
heads point to nuclear iASPP. Scale bar repre-
sents 20 mm.
(E) iASPP in human melanoma cell lines with or
without 10 mM nocodazole treatment for 16 hr was
immunoblotted.
See also Figure S2.
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data not shown). Phosphoproteome analysis of HeLa cells also
reported upregulation of S84 and S113 phosphorylation of
iASPP during mitosis (Olsen et al., 2010). Thus, S84 and S113
are phosphorylated by cyclin B1/CDK1 both in vitro and in vivo,
and their phosphorylation retards iASPP’s migration.
S84/S113 Phosphorylation of iASPP Promotes iASPP
Nuclear Localization by Preventing N- and C-Terminal
Self-Interaction
Our previous structural study showed that iASPP’s C-terminal
p53 binding domain can be masked by a peptide (GSPRKARR)
within iASPP (residues 615–622) (Robinson et al., 2008). This
peptide shares high sequence similarity with the N-terminal
region of iASPP, where S84 (GSPRKAAT) is located. Structural
modeling predicted that iASPP’s N-terminal domain may
interact with its C terminus, and phosphorylation of iASPP at
S84 may interfere with this (Figure S4A). Purified iASPP(1–240)
but not iASPP(249–482) was found to interact with the purified
iASPP C-terminal fragment, iASPP(625–828), which contains
the ankyrin repeat and SH3 domains. Under the same condi-
tions, iASPP(1–240) did not interact with the C terminus of
ASPP2(905–1128), which has high sequence and structuralCancer Cell 23, 618–similarity to iASPP’s C terminus (Fig-
ure 4A). Using iASPP variants singly
and doubly mutated at S84, S113, and
S120 sites, it was seen that residues
S84 and S113, but not S120, are involved
in this N- and C-terminal interaction of
iASPP, as Ala mutation of S84 and
S113 weakened the interaction. Phos-
phorylation mimetic mutations S84D
and S113D efficiently abrogated this
interaction (Figure 4B).Ras and E1A immortalized iASPP-deficient mouse embryonic
fibroblasts (Ppp1r13l/MEFs) were transfected with N-terminal
iASPP(1–478) and treated with nocodazole to induce posttrans-
lational modification and slow migration of transfected iASPP
(1–478). The resulting lysates were incubated with purified
recombinant iASPP C-terminal fragment, iASPP(625–828).
iASPP(625–828) selectively bound nonmodified, fast-migrating
N-terminal iASPP (Figure 4C). When purified recombinant
iASPP(1–240) was incubated with nocodazole-treated H1299
lysates, it specifically bound to nocodazole-induced modified,
slow-migrating endogenous iASPP with an exposed C terminus
(Figure 4D).
In a denaturing SDS-PAGE gel, iASPP migrated as a single
100 kDa band in normal growing H1299 cells, but as double
bands on nocodazole treatment. In a nondenaturing gel, iASPP
from the same cells migrates as a single 250 kDa band. In noco-
dazole-treated H1299 cells, iASPP migrates as two bands
differing in size (one110 kDa, the other 250 kDa), almost double
the apparent size of fast-migrating iASPP (Figure 4E). Although
this is not direct proof, the results suggest that in normal growing
H1299 cells, iASPP may exist as an anti-parallel homodimer.
Upon S84/S113 phosphorylation, the N- and C-terminal self-
interaction is disrupted, resulting in iASPP monomer formation.633, May 13, 2013 ª2013 Elsevier Inc. 621
Figure 3. Phosphorylation of iASPP at S84/
S113 by Cyclin B1/CDK1 Contributes to
iASPP Slow Migration
(A) Cells stably expressing iASPP(1–478)-V5 and
iASPP(482–828)-V5 were treated with the indi-
cated agents. iASPP fragments were detected by
anti-V5 antibody.
(B) GST pull-down assay to detect the binding
between Cyclin B1/CDK complex and purified
GST-iASPP(1–240), GST-iASPP(249–482), or
GST-Bin1 (40–372).
(C) Purified Histone H1 or GST-tagged proteins
were incubated with cyclin B1/CDK1 complex and
[g-32P]-ATP in an in vitro kinase assay as indi-
cated. [g-32P] signal is shown in g-32P panel.
(D) Purified GST-iASPP(1-240) or indicated
mutants were subjected to cyclin B1/CDK1 in vitro
kinase assay as for (C). Bar graph values are
mean ± SD of g-32P signal from two independent
experiments.
(E) IGR37 or IGR39 cells stably expressing
V5-tagged wild-type or mutant iASPP were lysed
and used to detect exogenous (V5 panel) and
endogenous (LX49.3 panel) iASPP.
See also Figure S3.
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peptides, (GSPRKAAT, 83–90 aa) and (GSPRKARR, 615–622
aa) suggests that C-terminal T722, L724, N813, and Y814 might
be contact residues for the N terminus (83–90 aa). Single and
double mutants were generated on these four residues.
iASPP(625–828)/T722A and iASPP(625–828)/L724A bound
N-terminal iASPP slightly less efficiently than WT iASPP(625–
828). iASPP(625–828)/N813A or iASPP(625–828)/Y814A had a
much reduced ability to bind iASPP(1–240). iASPP(625–828)/
T722A/N813A, iASPP(625–828)/T722A/Y814A, iASPP(625–
828)/L724A/N813A, and iASPP(625–828)/L724A/Y814A almost
lost their ability to interact with iASPP(1–240) in pull-down
assays. Mutant iASPP(625–828)S754A, which has a mutation
outside the putative binding region, can fully interact with
iASPP(1–240). This study identifies N813 and Y814 as two
key residues that interact with N-terminal iASPP (Figures 4F
and S4B).
To test whether N- and C-terminal self-interaction prevents
iASPP nuclear entry, digitonin-permeabilized H1299 cells (with
permeable cell membranes and intact nuclear membranes)
were used for in vitro nuclear entry assays using-FITC labeled
iASPP(625–828). FITC-labeled ASPP2(905–1128) was used as
a negative control. Both C-terminal iASPP and ASPP2 can enter
the nucleus with high efficiency (Sachdev et al., 1998; Slee et al.,
2004). Preincubation with increasing amounts of nonlabeled
N-terminal iASPP(1–240) prevented the nuclear entry of FITC-
labeled iASPP(625–828). Under the same conditions, preincuba-622 Cancer Cell 23, 618–633, May 13, 2013 ª2013 Elsevier Inc.tion of iASPP phosphomimetic mutant
iASPP(1–240)S84D/S113D failed to
affect the nuclear entry efficiency of
FITC-labeled iASPP(625–828). iASPP(1–
240) affected the nuclear entry of
iASPP(625–828) but not ASPP2(905–
1128) (Figure 4G). iASPP(S84D/S113D)showed more nuclear localization than WT iASPP and iASPP
(S84A/S113A) in Ppp1r13l/ MEFs (Figure 4H). Nuclear locali-
zation of iASPP(S84A/S113A) and iASPP(S84D/S113D) was
also observed in H1299 and WM278 cells, although differences
in cellular distribution between iASPP and its mutants were
less dramatic in these cells. Transfected iASPP expression pat-
terns agreed with those of endogenous iASPP:iASPP-V5 was
detected in both the cytoplasm and nucleus in WM278 cells,
but mainly in the cytoplasm in H1299 (Figure S4C).
Phosphomimetic iASPP, iASPP(S84D/S113D), Is More
Potent to Bind and Inhibit p53 Than WT iASPP
The abilities of iASPP and iASPP(S84D/S113D) to bind p53
were compared using in vitro translated iASPP and recombi-
nant p53. Figure 5A shows that iASPP(S84D/S113D) binds
p53 with greater affinity than iASPP in vitro. When transfected
into p53 null H1299 cells, iASPP(S84D/S113D) also bound
cotransfected p53 more effectively (Figure 5B). In Saos-2
cells, which are p53 null and express lower levels of iASPP
than H1299 cells (Bergamaschi et al., 2006a), transfected
iASPP(S84D/S113D) was more active than iASPP in inhibiting
exogenous p53-mediated transcription on the promoters of
p53 target genes PIG3, BAX, and PUMA. Neither iASPP nor
iASPP(S84D/S113D) inhibited p53’s transcriptional activity on
the CDKN1A, which encodes p21CIP1 (Figure 5C). Similarly,
iASPP(S84D/S113D) was more active than iASPP in inhibiting
the transcriptional activity of endogenous p53 in MCF7 and
Figure 4. S84/S113 Phosphorylation of iASPP Promotes iASPP Nuclear Localization by Preventing N- and C-Terminal Self-Interaction
(A) Purified GST-iASPP(1–240) or GST-iASPP(249–482) was incubated with purified His-iASPP(625–828) and His-ASPP2(905–1128), followed by GST pull-down
assays.
(B) Purified GST-iASPP(1–240) or mutants was incubated with purified His-iASPP(625–828) and His-ASPP2(905–1128), followed by GST pull-down assays.
(legend continued on next page)
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(Figure S5A and S5B).
Apoptosis was induced in both primary and immortalized
Ppp1r13l/ MEFs by p53 inducers such as Nutlin3, UV, etopo-
side, or cisplatin. This was largely p53-dependent, as p53 RNAi
abolished treatment-induced apoptosis (Figure S5C). iASPP and
mutant iASPP(S84D/S113D) were introduced to immortalized
Ppp1r13l/ MEFs competent in p53-mediated apoptosis. The
presence of iASPP or iASPP(S84D/S113D) had little impact on
cell survival in DMSO-treated cells. On treatment with Nutlin3,
apoptosis was detected in immortalized Ppp1r13l/ MEFs
transfected with control vector, based on an increase in c-cas-
pase 3 (cleaved caspase 3 onD175) and decrease in procaspase
3. iASPP caused a minimal decrease in c-caspase 3 expression
under these conditions. The presence of iASPP(S84D/S113D)
resulted in a clear decrease in c-caspase 3 and a small increase
in procaspase 3 levels, and caused the biggest reduction in the
levels of c-caspase 3 in comparison to those detected in vector
or iASPP-expressing cells exposed to 10 J/m2 UV. Clear
decreases in the expression of PIG3, BAX, and PUMA, but not
CDKN1A, were observed in Ppp1r13l/ MEFs expressing
iASPP(S84D/S113D), compared to those expressing vector or
iASPP (Figure 5D). Thus, iASPP(S84D/S113D) is more potent
than iASPP in inhibiting apoptosis in response to Nutlin3 or UV
treatments.
Wild-Type p53-Expressing Melanoma Cells Express
High Levels of MDM2 and S84/S113 Phosphorylated
Nuclear iASPP
To confirm that the observed alterations in iASPP’s location and
function are at least partly caused by modifications in the region
containing S84 and S113, we generatedmousemonoclonal anti-
iASPP antibody LX128.5 with an epitope mapped within the
identified region (residues 81–130, Figure S6A). LX49.3 recog-
nizes an iASPP epitope outside the modified region. Only fast-
migrating cytoplasmic iASPP was recognized by LX128.5
(Figure 6A). Modification of iASPP on S84 and S113 destroys
this epitope. Both nuclear and slow-migrating iASPP, as well
as iASPP(S84D/S113D), lost the epitope recognized by
LX128.5, which was previously recognized by LX49.3 (Figures
S6B and S6C). Comparing this to the expression patterns of
iASPP in the same panel of 18 melanoma lines (Figure S6D),
we concluded that slow-migrating iASPP detected by LX49.3
lost the LX128.5 epitope. Slow-migrating iASPP detected in
this panel of cell lines is thus likely to be phosphorylated nuclear
iASPP, modified in the region that contains S84 and S113.
To test whether cyclinB/CDK1-phosphorylated nuclear iASPP
contributes to p53 inactivation in melanomas, the panel of 18(C) Ras + E1A transformed Ppp1r13l/MEFs stably expressing iASPP(1–478)-V
His-iASPP(625–828) and subjected for His pull-down assays.
(D) H1299 cells were treated with nocodazole for 16 hr. Cell lysates were mixed
(E) iASPP migration from DMSO- or nocodazole-treated H1299 cells was determ
(F) Purified His-iASPP(625–828) or mutants were mixed with GST-iASPP(1–240),
(G) Purified His-iASPP(625–828)-FITC or His-ASPP2(905–1128)-FITC were preinc
iASPP(1–240)S84D/S113D as indicated, and applied to digitonin-treated H1299 c
FITC-positive nuclei after treatment derived from three independent experiments
(H) Immunofluorescence staining of stably expressed iASPP mutants (V5 tagged
See also Figure S4.
624 Cancer Cell 23, 618–633, May 13, 2013 ª2013 Elsevier Inc.lines used above was analyzed for iASPP, p53, and cyclin B1
expression. In contrast to human primary melanocytes, iASPP,
MDM2, and cyclin B1 are overexpressed in most melanoma
lines. Increased expression of MDMX and p53 was detected in
some lines, whereas CDK1 expression was more constant (Fig-
ure 6B). Of note, 91% (10/11) of WT p53-expressing melanoma
lines expressed a high proportion of phosphorylated iASPP
(>50%), whereas 86% (6/7) of those expressing mutant p53
had a lower proportion (<20%, Figure 6B). Approximately 80%
(9/11) of WT p53-expressing lines had detectable to high levels
of MDM2, whereas only 45% expressed detectable MDMX
(5/11) under the same conditions. Approximately 70% of the
WTp53 lines expressed relatively high levels ofMDM2 and phos-
phorylated nuclear iASPP, many of which also expressed rela-
tively high levels of cyclin B1. Levels of phosphorylated iASPP
were not linked to the expression levels of other cell cycle regu-
lating proteins such as CDK1, CDK2, cyclin A, cyclin E, p16, p21,
or p27 (Figures S6E and S6F). Elevated phosphorylated iASPP
expression was not due to an increase in mitosis, as the expres-
sion levels of phosphohistone H3 were almost constant among
most of the cell lines tested, and differed from cyclin B1 levels
(Figure S6F). The percentage of G2/M cells detected in the panel
of melanoma lines did not correlate with levels of cyclin B1 or
iASPP modification, although high levels of cyclin B1 associated
with high levels of modified iASPP (Figures S6G and S6H).
Consistent with this in vitro finding, we observed that weak
cyclin B1 and cytoplasmic iASPP, or strong cyclin B1 and high
nuclear iASPP expression, often occur in the same human
melanoma samples (Figures 6C and 6D). To investigate the cor-
relation of cyclin B1 and nuclear iASPP in primary tumors and
metastases, samples were divided into six groups as indicated
(Figures 6E and 6F). Weak cyclin B1 and low nuclear iASPP
expression was observed in 81% of primary melanomas (26/
32), whereas 83% express strong cyclin B1 and high nuclear
iASPP in lymph node metastases (5/6) (Figure 6E). In a cohort
of 66 melanoma patients, high nuclear iASPP was significantly
associated with poor survival. A trend to association of high
cyclin B1 with poor survival was seen, but a larger independent
cohort is needed to conclude whether strong cyclin B1+nuclear
iASPP is associated with the worst survival outcome (Figure 6F).
Restoring p53 by Inhibiting MDM2 and iASPP
Suppresses Melanoma Growth In Vitro and In Vivo
Knocking down cyclin B1 with RNAi abolished slow-migrating
iASPP in the presence of nocodazole (Figure 7A). Increased
expression of cyclin B1, but not CDK1, induced nuclear localiza-
tion of iASPP in H1299 cells, agreeing with the fact that CDK1 is
in excess in cells, cyclin B1 dictates the kinase activity of cyclin5 were treated with nocodazole for 16 hr. Cell lysates were mixed with purified
with purified GST-iASPP(1–240) and subjected for GST pull-down assays.
ined in denaturing or nondenaturing gels as indicated.
followed by GST pull-down assay.
ubated without (Ctr) or with increasing amounts of GST-iASPP(1–240) or GST-
ells. Scale bar represents 20 mm. Bar graph (mean ± SD) shows percentage of
. Greater than 100 cells were counted.
) in Ras + E1A transformed Ppp1r13l/ MEFs. Scale bar represents 20 mm.
Figure 5. Phosphomimetic iASPP, iASPP(S84D/S113D), Is a More Potent Binder and Inhibitor of p53 Than WT iASPP
(A) His-p53(2–293) and in vitro-translated iASPP-V5 (WT) or iASPP(S84D/S113D)-V5 (S84D/S113D) in a His pull-down assay. BSA was used as a negative
control.
(B) iASPP-V5 (WT) or iASPP(S84D/S113D)-V5 (S84D/S113D) and p53 were cotransfected in H1299 cells (input), followed by coimmunoprecipitation using p53
antibody and IgG.
(C) Effects of iASPP (WT) or iASPP(S84DS113D) on the transcriptional activity of exogenous p53 in Saos-2 cells measured using a panel of reporters containing
the promoter of PIG3, BAX, PUMA, orCDKN1A. Bar graph showsmean ± SD from three independent experiments (*p < 0.05). Lower panels: expression levels of
transfected iASPP and p53 are indicated.
(D) Ras + E1A transformed Ppp1r13l/ MEFs stably expressing vector (Vec), iASPP(WT), or iASPP(S84D/S113D) (S84D/S113D) were subjected to various
treatments for 24 hr as indicated. Protein levels of cleaved caspase 3 (c-caspase 3) and p53 targets were detected by immunoblotting.
See also Figure S5.
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Restoring p53 Function in MelanomaB1/CDK1 (Figure 7B). A panel of 15 G2/M kinase inhibitors was
tested for their ability to prevent nocodazole-induced iASPP
modification in H1299 cells. At 2–10 mMconcentrations, most in-
hibitors against Aurora kinase, Polo like kinase (PLK), Pim1, or
Mps1 kinase failed to abrogate nocodazole-induced iASPP
modification (Figures 7C and S7A). In contrast, several inhibitors
known to affect cyclin B/CDK1 activity inhibited iASPPmodifica-
tion. The most potent inhibitor of iASPP modification in the pres-
ence of nocodazole was JNJ-7706621 (JNJ), a CDK1 inhibitor
with an in vitro IC50 of 9 nM for cyclin B/CDK1 (Emanuel et al.,
2005). The CDK2 inhibitor Roscovitine only weakly affected
iASPPmodification (Figures 7C and S7A). To provide supporting
evidence that p53 selectively binds cyclin B1/CDK1-phosphory-
lated nuclear iASPP, WM278 cells were treated with DMSO,
nocodazole, or JNJ, and treated cell lysates incubated in the
presence or absence of a Ser/Thr phosphatase (calf intestine
alkaline phosphatase [CIP]) before immunoprecipitation. JNJ
alone reduced the amount of modified iASPP, whereas nocoda-
zole increased it. CIP treatment abolished nocodazole-induced
iASPP modification. p53 failed to coimmunoprecipitate iASPP
in JNJ, control+CIP- and nocodazole+CIP-treated lysates,
although it was efficiently coimmunoprecipitated with modified
iASPP in both control and nocodazole-treatedWM278 cells (Fig-
ure 7D). These data illustrate that p53 selectively binds phos-
phorylated iASPP in vivo.
Cells were treated with various concentrations of Nutlin3
to identify concentrations that induce maximal p53 expres-
sion (Figures S7B and S7C). The ability of JNJ to reactivate WT
p53 function was also tested in a panel of 11 melanoma
lines in which the mutation status of p53, NRAS, and BRAF
were confirmed by sequencing. When WT p53, NRAS, and
BRAFV600E-expressing WM278 cells were treated with Nutlin3
or JNJ alone, a small percentage of apoptotic cells were induced
with limited cell growth suppression, despite induction of p53
expression. However, iASPP RNAi or JNJ resulted in significant
increases in Nutlin3-induced apoptosis, determined by the pres-
ence of cells expressing Annexin V (Figure 7E) and colony forma-
tion assay (Figure 7F) or containing Sub-G1 DNA (Figure S7D).
Apoptosis induced by JNJ+Nutlin3 was iASPP and p53-depen-
dent: in the presence of iASPP RNAi, JNJ failed to further
enhance Nutlin3-induced apoptosis. p53 RNAi largely prevented
bothapoptosis andgrowth suppression inducedbyJNJ+Nutlin3.
The synergistic effects of JNJ and Nutlin3 in inducing apoptosis
and suppressing colony formation were observed in an addi-
tional nine WT p53-expressing melanoma lines, but not mutant
p53-expressing SK-MEL37 cells (Figures S7E–S7H). The
observed synergistic effects of JNJ and Nutlin3 are largely
iASPP- and p53-dependent, regardless of BRAF mutation.Figure 6. WT p53-Expressing Melanoma Cells Express High Levels of
(A) Immunofluorescence staining and immunoblot to show iASPP cellular locali
LX128.5 as indicated were used for iASPP detection.
(B) Lysates from indicated melanoma cell lines were immunoblotted with indica
(mean ± SD from two independent experiments) and p53 status (indicated on the
were labeled with stars, triangles, and hollow triangles, respectively.
(C–F) Analysis in 142 human melanoma tissue array cores. Two representative iAS
iASPP expression levels in samples that expressing low, medium, or high cyclin
various cyclin B1 levels and nuclear iASPP levels from lymph nodemetastases an
cyclin B1 levels and nuclear iASPP levels (F).
See also Figure S6.The identified regulation of p53 by iASPP and MDM2 exists in
both human WM278 and mouse B16 melanoma cells. We thus
tested whether restoring p53 function is able to suppress the
growth of highly aggressive B16 melanomas in immune compe-
tent C57BL/6 syngeneic mice. B16 cells treated with DMSO,
Nutlin3, JNJ, and Nutlin3+JNJ were injected into the flanks of
C57BL/6 mice and tumors analyzed after 13 days. Tumors
derived from JNJ-, Nutlin3-, or JNJ+Nutlin3-treated B16 cells
were around 34%, 59%, or 14% of those derived from the
DMSO group, respectively. JNJ treatment appears more potent
in inhibiting B16 growth in vivo than in colony assays (Figures 7G
and 7H). The underlying cause of this discrepancy is unknown.
The ability of Nutlin3+JNJ to inhibit B16 melanoma growth
in vivo was further tested by inoculating untreated B16 cells
into C57BL/6 mice, 3 days (Figures S7I–S7K) or 7 days (Figures
7I–7K) prior to intraperitoneal administration of DMSO, Nutlin3
(40 mg/kg), JNJ (30 mg/kg), or Nutlin3+JNJ every 2 days as indi-
cated. Treatment with Nutlin3+JNJ suppressed tumor weight/
size of B16 melanomas by 61%–66% compared to DMSO.
Administration of Nutlin3 from day 3 or 7 after B16 inoculation
suppressed melanoma growth by 22% or 5%, but injection of
JNJ at both time points suppressed melanoma growth by 36%
or 30%, respectively (Figures 7J and S7J). These data suggest
that the timing of MDM2 inhibition may affect Nutlin3 efficacy,
but the efficacy of JNJ or JNJ+Nutlin3 is less affected by first
administration time.
Both cytoplasmic and nuclear iASPP were detected in DMSO-
treated B16 tumors (Figure 7K). Under the same conditions, p53
expression was almost undetectable. Treatment with JNJ clearly
reduced nuclear iASPP expression in a number of B16 tumor
cells but had no effect on p53 expression. Nutlin3 treatment
induced nuclear p53 expression and had minimal impact on
iASPP expression. Treatment with JNJ+Nutlin3 resulted in a
reduction in nuclear iASPP and an increase in nuclear p53
(Figure 7K). This illustrates that JNJ’s tumor suppressive effect
associates with reduced nuclear iASPP expression in B16 tumor
cells in vivo. Combined treatment with JNJ and Nutlin3 restores
the p53’s tumor suppressive function and inhibits melanoma
growth in vivo.
Restoring the Apoptotic Function of p53 Cooperates
with BRAFV600E Inhibition to Suppress Human
Melanoma Cell Growth In Vitro and In Vivo
To examine whether restoring WT p53 function and concurrently
inhibiting BRAFV600E has cooperative effects, WM278, Me300,
A375P, and SK-MEL37 were treated with increasing amounts of
vemurafenib. One micromolar of vemurafenib was identified as
the optimal concentration to induce apoptosis in these cellsMDM2 and S84/S113 Phosphorylated Nuclear iASPP
zation and mobility in indicated cells. Scale bar represents 20 mm. Lx49.3 or
ted antibodies. The bar graph shows the percentage of iASPP modification
bar). Cell lines with WT p53, overexpressed MDM2, or overexpressed MDMX
PP and cyclin B1 staining. Scale bar represents 50 mm (C). The median nuclear
B1 (U = 340.500, r = 0.28, p < 0.05) (D). Percentage of samples expressing
d primary tumors, respectively (E). Survival curve of patients expressing various
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Figure 7. Restoring p53 by Inhibiting MDM2 and iASPP Suppresses Melanoma Growth In Vitro and In Vivo
(A) Immunoblot of iASPP in H1299 cells treated with cyclin B1 RNAi in the presence or absence of 10 mM nocodazole.
(B) Immunofluorescence staining shows localization of transfected cyclin B1 or CDK1 and endogenous iASPP in H1299 cells. Cells expressing transfected cyclin
B1 or CDK1 are labeled by white arrows. Scale bar represents 20 mm.
(legend continued on next page)
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Restoring p53 Function in Melanoma(Figure S8A and data not shown). The highest levels of apoptosis
(Figures 8A and S8B) and growth suppression (Figures 8B and
S8C) were observed in WM278 cells when JNJ, Nutlin3, and
vemurafenib were used together to induce the expression of pro-
apoptotic genes such as BAX and PUMA (Figure S8D; note that
the results in Figures 7E and 7F were controls for Figures 8A and
8B, hence part of Figures 8A and 8B are identical to that of Fig-
ures 7E and 7F). Vemurafenib alone induced apoptosis and
growth suppression in WM278 cells, possibly achieved by
inhibiting Mcl-1 expression (Figure S8D). Similar results were
obtained in BRAFV600E-expressing A375P, Me300, and SK-
MEL26 cells, but not the panel ofWTBRAF-expressing cells (Fig-
ures S8E and S8F). MEK is a direct downstream kinase of BRAF.
Interestingly, MEK inhibitor U0126 cooperated with JNJ+Nutlin3
in inducing apoptosis and growth suppression to a similar extent
as vemurafenib. No additive effect was observed between
vemurafenib and U0126 (Figures 8C, 8D, and S8G).
The therapeutic potential of the combination of vemurafenib,
JNJ, and Nutlin3 was tested using the A375P human melanoma
xenograft model. A375P cells treated with DMSO, Nutlin3, JNJ,
and Nutlin3+JNJ in the presence or absence of vemurafenib
were injected into the flanks of nude mice for 28 days. Experi-
ments were terminated when tumors reached 1 cm in diameter
in the DMSO-treated group. Tumors derived from Nutlin3-,
JNJ-, or JNJ+Nutlin3-treated A375P cells were 1%, 30%, or
58% smaller than those from the DMSO group, respectively (Fig-
ures 8E and 8F). Tumors derived from vemurafenib, Vem+Nut,
Vem+JNJ, and Vem+JNJ+Nut were 39%, 40%, 59%, and
75% smaller, respectively.
A375P cells were inoculated into nude mice for 10 days to
develop visible tumors prior to the administration of various com-
binations of compounds. Intraperitoneal injection of the indi-
cated combinations of 20 mg/kg vemurafenib, 30 mg/kg JNJ,
and 40 mg/kg Nutlin3 had no visible impact on animal health
and weight loss (Figure S8H). Importantly, injection of Nut+JNJ
or Nut+JNJ+Vem suppressed A375P melanoma growth by
58% and 88% in size (Figure 8G) and 67% and 88% in
weight (Figure 8H) compared to DMSO controls. Under the
same conditions Nutlin3, JNJ, or vemurafenib injection alone
only inhibited A375P melanoma growth by 4%, 41%, and 51%
in weight, respectively. Coinjection of Vem+JNJ or Vem+Nut
achieved similar growth suppression, inhibiting tumor growth
by66%or69% in weight (Figure 8H). Finally, immunofluores-
cent staining confirmed that intraperitoneal injection of JNJ can
reduce nuclear iASPP expression, whereas Nutlin3 induces p53
expression in A375P melanoma cells in vivo (Figure S8I). These
data show that restoring the apoptotic function of p53, together(C) Immunoblot of iASPP in H1299 cells treated with indicated compounds for 1
(D) WM278 cells treated with DMSO (C), 0.4 mM JNJ (J), or 10 mM nocodazole (N)
phosphatase (CIP) for 1 hr, followed by p53 coimmunoprecipitation.
(E and F)WM278 cells were treatedwith JNJ, Nutlin3, or a combination in the prese
percentage of Annexin V positive cells (E) and percentage of treated cells that form
experiments. *p < 0.05.
(G and H) Colonies (G) and tumors (H) formed from treated B16 cells as indicate
(I–K) Untreated B16 cells were subcutaneously injected into flanks of mice at day
administration (indicated by arrows) and tumor sizemeasurement (I) was repeated
of iASPP and p53 (K) of tumors on day 13. Graphs of showmean ± SD (*p < 0.05, n
from Topro staining. Scale bar represents 20 mm.
See also Figure S7.with BRAFV600E inhibition, can achieve additive effects in sup-
pressing melanoma growth in vitro and in vivo.
DISCUSSION
Here, we show that p53 is inhibited by cyclin B1/CDK1-phos-
phorylated nuclear iASPP, in addition to MDM2, in the majority
of wild-type p53-expressing melanomas (Figure 8I). The tumor
suppressive function of p53 in melanomas can be restored by
concurrently inhibiting both MDM2 and iASPP phosphorylation,
using Nutlin3 and JNJ, respectively, both in vitro and in vivo.
Our results further suggest that targeting two independent path-
ways may represent a promising melanoma treatment strategy
(Figure 8J).
The action of JNJ contrasts with a recent finding that Nutlin3
specifically cooperates with VX-680, an Aurora kinase inhibitor,
to kill mutant, but not WT p53-expressing, cells (Cheok et al.,
2010). The observed specificity of JNJ and VX-680 for WT and
mutant p53 is intriguing. The selective impact of JNJ on WT
p53 when combined with Nutlin3 may be linked to the phosphor-
ylation of iASPP at SP sites favored by CDK family kinases
(Johnson, 2011). Aurora, Plk1, Pim1, and Msp1 do not efficiently
phosphorylate SP sites, and inhibitors of Aurora, Plk1, Pim1,
and Msp1 kinases failed to inhibit nocodazole-induced iASPP
modification. Several phosphoproteome studies have identified
phosphorylation of iASPP on S102, S110, S119, and S120, in
the region that interacts with iASPP’s C terminus. Phosphoryla-
tion on multiple sites may thus be responsible for the large
mobility shift observed. However, the ability of iASPP(S84A/
S113A) to abrogate slow-migrating iASPP in IGR37 cells, which
express slow-migrating endogenous iASPP, suggests that S84
and S113 are the two key phosphorylation sites required to
initiate or prime other iASPP modifications.
The observed regulation of iASPP’s self-interaction and local-
ization is p53-independent. However, both p53 and iASPP
are substrates of cyclin B1/CDK1. Phosphorylation of p53 at
Ser315 by cyclin B1/CDK1 or cyclin A/CDK2 in human and
Ser312 in mouse contributes to the apoptotic and tumor sup-
pressive function of p53 in vitro and in vivo (Fogal et al., 2005;
Slee et al., 2010; Wang and Prives, 1995). Hence phosphoryla-
tion of p53 may regulate iASPP/p53 interaction and p53’s
function in G2/M. iASPP is also able to bind and regulate the
p53 family members p63 and p73 (Bell and Ryan, 2008; Notari
et al., 2011). Thus, the observed regulation of iASPP/p53 interac-
tion is likely to apply to p63 and p73. Very little is known about
p63 in human melanomas, but p73 was reported to play an
important role in mutant p53-expressing melanoma cells (Rudolf6 hr.
for 16 hr were lysed and incubated with (+) or without () calf intestine alkaline
nce or absence of control, iASPP and p53 RNAi, as indicated. Bar graphs show
ed colonies (F). Bar graphs (mean ± SD) were derived from three independent
d. Bar graphs show mean ± SD (*p < 0.05, n = 4/group).
1. Indicated compounds were intraperitoneally injected on day 7. Compound
every 2 days from day 7 onward.Weights (J) and immunofluorescence staining
= 4/group). White dotted circles in (K) show representative nuclear rim derived
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p63 and iASPP/p73 interaction is regulated, and whether it can
influence p63- and p73-mediated cell cycle progression and
genome stability.
A whole genome-based array showed that cyclin B1 was
highly upregulated in human melanoma cells (Avery-Kiejda
et al., 2011). Increased cyclin B1 protein levels were also re-
ported in metastatic melanoma tissue sections compared to
primary melanomas (Georgieva et al., 2001). Increased cyclin
B1 expression is not limited to melanomas, and was detected
in esophageal squamous cell carcinomas that contribute to
metastasis (Song et al., 2008). These studies corroborate our
finding that nuclear iASPP is significantly associated with meta-
static melanoma. Deregulation of cyclin B1/CDK1 and increased
iASPP S84 and S113 phosphorylation are likely to occur in other
tumor types. Hence JNJ+Nutlin3 may reactivate p53 in other WT
p53-containing tumors expressing high levels of cyclin B1.
Restoration of WT p53 function and inhibition of BRAFV600E
represents ameans of enhanced cell killing in humanmelanoma.
Strategies that target both p53-dependent and -independent
pathways to inhibit cell growth or induce cell death may be fertile
grounds for synergistic killing of the 50% of tumor cells that
express WT p53.
EXPERIMENTAL PROCEDURES
Plasmids, Antibodies, Cell Lines, Compounds and Mice
See Supplemental Experimental Procedures.
Immunoprecipitation, Pull-Down, Immunoblotting, Cell Shake-Off,
and In Vitro Cyclin B1/CDK1 Kinase Assay
Cells were lysed in NP40 buffer for immunoprecipitation or 8 M urea buffer for
immunoblotting. For pull-down assays, beads preincubated with purified His-
or GST-tagged proteins were mixed with 450 ml NP40 buffer containing either
5 mg/ml purified proteins or 2 mg/ml cell lysate.
H1299,WM278, or melanocytes were preseeded in T175 flasks for 16 hr and
heavily shaken five times. Floating and adherent cells were collected. iASPP
expression was detected by immunoblotting or immunofluorescence staining
after cytospin. Recombinant N-terminal iASPP and itsmutants were incubated
with cyclin B1/CDK1 complex in a kinase assay mixture for 10 min at room
temperature (RT). See Supplemental Experimental Procedures for details.
Mass Spectrometry, FITC Conjugation, and In Vitro Nuclear Import
Assay
H1299 cells were grown and lysed in NP40 buffer. Protein lysate (40 mg) was
immunoprecipitated with 100 ml crosslinked LX49.3-proteinG Sepharose
beads before SDS-PAGE. Isolated gel bands were subjected to trypsinFigure 8. Restoring the Apoptotic Function of p53Cooperateswith BRA
and In Vivo
(A and B) Bar graphs show the percentage of Annexin V positive cells (A) and pe
0.4 mMJNJ, 20 mMNutlin3, 1 mMvemurafenib, or combinations in the presence of
from three independent experiments. *p < 0.05.
(C and D) Bar graphs show the percentage of Annexin V positive cells (C) and p
0.4 mMJNJ, 10 mMNutlin3, 1 mMvemurafenib, 2 mMU0126, or combinations. Bar g
(E and F) In vitro-treated A375P cells were subcutaneously injected into flanks of
Mice were culled on day 28 and isolated tumors weighed (F). Graphs show mea
(G and H) Untreated A375P cells were subcutaneously injected into flanks of nud
tumor size measurement (G) was repeated every 3 days from day 10 onward. Mic
SD (*p < 0.05, n = 6/group). Lower panel shows tumors derived.
(I) Schematic diagrams showing cyclin B1/CDK1 phosphorylation controls iASPP
and red stars (*) indicate the C- and N-terminal contacting residues.
(J) Schematic diagrams showing JNJ, Nut, and Vem synthetically suppress mela
See also Figure S8.digestion and HPLC purification before 3D high capacity ion trap mass spec-
trometer analysis.
Purified GST, His-iASPP(625–828), or His-ASPP2(905–1128) were conju-
gated with FITC. In vitro nuclear import assays were carried out as described
(Van Impe et al., 2008). See Supplemental Experimental Procedures for
details.
p53, BRAF, NRAS Sequencing, Transactivation Assay, and Knock
Down of Cyclin B1, p53, and iASPP
mRNA and genomic DNA were extracted from all melanoma cell lines. TP53,
BRAF, and NRAS were amplified by PCR and the products sequenced.
Cells plated in 12-well plates were transfected with 250 ng of luciferase
reporter plasmid, 50 ng of p53, and 100 ng of iASPP expression plasmids
per well as indicated. Luciferase reporter activities were detected using a
luciferase assay kit (Promega).
siRNA of cyclin B1, p53, or iASPP was reverse transfected into cells using
DharmaFECT 1 Transfection Reagent kit. See Supplemental Experimental
Procedures for details.
FACS Analysis, Colony Formation, and Xenograft Assay
Cells were incubated with either DMSO or 0.4 mM JNJ for 48 hr to block
iASPP modification. Cells were digested and transfected with siRNA using
DharmaFECT 1 Transfection Reagent kit and seeded on 6-well plates in fresh
medium containing DMSO, 0.4 mM JNJ, 10–20 mM Nutlin3, 1–5 mM vemurafe-
nib, or indicated combinations for 72 hr. Treated cells were collected and used
for immunoblotting, FACS analysis, or colony formation. Cells (1–5 3 106)
treated as above were used for mouse xenograft assay. All animal experiments
were approved by the animal use ethical committee of Oxford University and
fully complied with UK Home Office guidelines. See Supplemental Experi-
mental Procedures for details.
Characterization of Anti-iASPP Antibodies, Immunohistochemistry
Staining, and Patient Survival Analysis
Human iASPP(1–240) was used to immunizemice and a panel of mousemono-
clonal anti-iASPP antibodies characterized as described previously (Freder-
sdorf et al., 1996; Slee et al., 2004). Melanoma tissue arrays were used to
detect iASPP or cyclin B1 expression using immunohistochemistry staining
(Notari et al., 2011). A multivariate Cox proportional hazards model was
used to analyze the association between high levels of nuclear iASPP and
patient survival. Experimental work on the clinical tissue used in this study
was conducted under approval from the Oxfordshire Research Ethics
Committee C (09/H0606/5). Written informed consent was obtained from all
subjects whose tumor tissue was used in this study. See Supplemental Exper-
imental Procedures for details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2013.03.013.FV600E Inhibition to Suppress HumanMelanomaCell Growth In Vitro
rcentage of treated cells that formed colonies (B) in WM278 cells treated with
control, iASPP, or p53 RNAi as indicated. Bar graphs (mean ± SD) were derived
ercentage of treated cells that formed colonies (D) in A375P cells treated with
raphs (mean ± SD) were derived from two independent experiments. *p < 0.05.
nude mice on day 1. Tumor size measurement was repeated every 3 days (E).
n ± SD (*p < 0.05, n = 4/group). Lower panel shows tumors derived.
e mice at day 1. Indicated compounds administration (marked by arrows) and
e were culled on day 28 and isolated tumors weighed (H). Graphs showmean ±
localization in interphase (interphase) or in G2/M cells (or melanoma cells). Blue
noma growth.
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